

INOVIO PHARMACEUTICALS, INC.  
Form 8-K  
September 10, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report**

**(Date of earliest event reported)**

**September 10, 2013**

**INOVIO PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction)**

**001-14888**  
**(Commission)**

**33-0969592**  
**(I.R.S. Employer)**

of incorporation)

File Number)

Identification No.)

1787 Sentry Parkway West

Building 18, Suite 400

Blue Bell, Pennsylvania

(Address of principal executive offices)

19422

(Zip Code)

Registrant's telephone number, including area code: (267) 440-4200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On September 10, 2013, we issued a press release to announce that we have entered into a Collaboration, Option and License Agreement dated as of September 9, 2013 (the Agreement) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche). A copy of the press release is attached as Exhibit 99.1 to this Form 8-K current report and is incorporated by reference into this Item 7.01. We will file a separate Form 8-K with respect to the Agreement to report the entry into a material definitive agreement under Item 1.01 of Form 8-K.

On September 10, 2013, we are holding a conference call at 8 a.m. eastern time to discuss the Agreement and our strategic partnership with Roche. The script for this conference call is attached as Exhibit 99.2 to this Form 8-K current report and is incorporated by reference into this Item 7.01.

Item 9.01. Financial Statements and Exhibits.

Exhibit

No.	Exhibit Description
99.1	Press Release dated September 10, 2013.
99.2	Script for Conference Call of September 10, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

By: /s/ Peter Kies  
Peter Kies,  
Chief Financial Officer

Date: September 10, 2013